Inve India ▾
SUSUPRIYA

Supriya Lifescience Q1 FY25 results (Apr–Jun 2024) and concall

Healthcare · Concall AI · Call held 12 Aug 2024

Company page: Supriya Lifescience share price, financials & guidance record

Source transcript

Supriya Lifescience delivered a robust Q1 FY25 performance, achieving 22% YoY revenue growth and significant margin expansion despite geopolitical uncertainties. The company's strategic shift towards regulated markets, broadened product portfolio, and backward integration initiatives are driving this growth. Capacity doubling and upcoming CDMO/CMO contributions are expected to fuel future expansion.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.